GlassScriptPhysician profile
Robert C Wille
NPI 1770565541
$1,189.03
in general payments reported to CMS, 2019-2025
18 companies · $17.47 in 2025
The $17.47 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $64.00 · 2022: $51.97 · 2023: $290 · 2024: $490 · 2025: $17.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $519.46 | 2019-2024 | Skyrizi, Mavyret, Linzess |
| Pfizer INC. | $109.69 | 2019-2024 | |
| Genzyme Corporation | $107.74 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.89 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $69.96 | 2019-2024 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.23 | 2019-2024 | Xifaxan |
| Qol Medical, LLC | $32.09 | 2023-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $26.44 | 2024 | Omvoh |
| Braintree Laboratories, INC. | $25.24 | 2019-2020 | |
| Vivus LLC | $22.24 | 2024 | Qsymia |
| Amgen INC. | $21.88 | 2023 | Avsola, Amjevita |
| Celgene Corporation | $18.27 | 2023 | Zeposia |
| Gilead Sciences, INC. | $17.74 | 2023 | |
| Celltrion USA INC. | $17.47 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $15.71 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $14.06 | 2024 | |
| Ferring Pharmaceuticals INC. | $13.05 | 2019 | |
| Merck Sharp & Dohme LLC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.